Clinical OMICS

MAR-APR 2017

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link: http://clinicalomics.epubxp.com/i/798822

Contents of this Issue

Navigation

Page 35 of 47

34 Clinical OMICs March/April 2017 www.clinicalomics.com In the Lab I n the fight against cancer, scientists and clinicians have looked toward novel approaches that provide a more com- prehensive understanding of the molecular mechanisms that drive the disease—all with the hope of uncovering new therapies that afford many patients a better quality of care. To that end, in August of 2015, the National Cancer Institute (NCI) began enrolling patients into a unique initiative that looked to analyze cancer patients' tumors for actionable mutations for which a targeted therapy already exists . The unique aspect is that patients were grouped based on their mutations and not their specific cancer—with the hope that treating these cancers on the basis of their mutational profile will be more effective. The program set up by NCI is called the Molecu- lar Analysis for Therapy Choice (NCI-MATCH) and is looking to exam- ine tumor samples from approximately 6,000 patients . The goals are ambitious, and complicated by the concerns expressed by many researchers about the complexity, accu- racy, and reproducibility of next-generation sequencing (NGS) for application in clinical trials . However, investiga- tors involved with NCI-MATCH set out to address whether the methodologies were valid that the clinical centers were using to iso- late, sequence, and ana- lyze the array of tumor samples being collected . Now, a recent report in The Journal of Molecular D i a g n o s t i c s — e n t i t l e d "Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Find- ing Clinical Trial"— confirms that the assay tailored for this trial is highly sensitive for detecting genetic muta- tions from a variety of tumor tissue and, for the first time, has been reproduced with accu- A Proper MATCH Report: New NGS Method Up to Snuff for Tumor Analysis in NCI-MATCH Clinical Trial

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - MAR-APR 2017